Drugs in MeSH Category Membrane Transport Modulators

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharm	PINDAC	pinacidil	CAPSULE, EXTENDED RELEASE;ORAL	019456-002	Dec 28, 1989		DISCN	No	No
Leo Pharm	PINDAC	pinacidil	CAPSULE, EXTENDED RELEASE;ORAL	019456-001	Dec 28, 1989		DISCN	No	No

Last updated: July 24, 2026

Market dynamics and patent landscape for drugs in NLM MeSH Class: Membrane Transport Modulators

Membrane transport modulators sit at the intersection of transporter biology, drug-delivery and disposition science, and high-value IP. The market is driven by (i) chronic indications where exposure control matters, (ii) transporter-selective mechanism-of-action (MoA) that supports narrow patent coverage, and (iii) FDA scrutiny over clinically meaningful inhibition/induction of major pathways. Patent estates across the class split into three dominant buckets: composition and formulation, transporter interaction (binding/modulation, substrate selectivity), and patient-selection or regimen method-of-use tied to transporter biomarkers.

What are membrane transport modulators and how do they move market share?

Membrane transport modulators encompass small molecules and biologics that alter the function of transporters involved in absorption, distribution, metabolism-related efflux/influx, and renal/hepatic clearance. Key commercial sub-areas include:

Which transporter families drive commercial spend?

• Drug efflux transporters (notably ATP-binding cassette transporters such as P-gp/ABCB1)
• Uptake transporters (e.g., OAT/OATP families)
• Ion transporters (clinically important in electrolyte and airway disease)
• Bile acid and nutrient transporters (gastrohepatic and metabolic indications)
• Monocarboxylate and amino acid transporters (oncology and metabolic crossover)

How does transporter selectivity affect pricing power?

Transporter modulators tend to command sustained pricing when they:

• Demonstrate clear clinical endpoints that are mechanistically aligned to the transporter target.
• Avoid “class-effect” safety issues seen with broad transporter inhibition.
• Maintain exposure control across patient subgroups (renal/hepatic impairment, drug-drug interaction risk).

How does lifecycle strategy look in this space?

Because transporter-specific MoA can limit the breadth of early patents, sponsors often layer:

• New salt forms, polymorphs, and solid-state forms
• Dose and regimen method-of-use tied to exposure targets
• Formulation changes that mitigate P-gp mediated efflux or alter release kinetics
• Combination approvals (co-therapy) supported by transporter interaction data

What patents protect membrane transport modulators across the typical estate?

Patent protection in this MeSH class is rarely a single monolith. Estates usually combine core claims around the transporter-modulating entity with secondary claims around drug product and use.

What types of patents dominate the transporter-modulator estate?

1. Composition of matter
   • Core active pharmaceutical ingredient (API) and analogs
   • Salts, hydrates, solvates, polymorphs
   • Co-crystals and polymorphic “fallback” positions
2. Method-of-treatment and method-of-use
   • Indication claims
   • Subgroup or dosing claims tied to biomarker status (e.g., transporter expression)
   • Regimens designed to manage drug-drug interactions and exposure
3. Formulation and delivery patents
   • Controlled release or delayed release profiles
   • Solubilizers and excipients that impact bioavailability
   • Particle engineering that changes permeability or efflux susceptibility
4. Process and manufacturing patents
   • Routes enabling specific polymorph selection
   • Scale-up processes that preserve target solid form
5. Combination patents
   • Fixed-dose combinations or co-administration regimens
   • Use claims that integrate a transporter modulator with another therapy

How many patents cover a typical transporter modulator?

A typical high-value estate (single marketed product) often has:

• 1–3 core composition families
• 3–10 formulation or solid-state families
• 2–6 method-of-use families
• 1–3 combination-specific families This leads to a portfolio count commonly in the 7–20+ patent document range at any given time, depending on claim survivability and terminal disclaimers.

How long does exclusivity last for membrane transport modulators in the US?

Exclusivity is split between statutory exclusivities (biologics and small molecules) and patent term. For small-molecule drugs, patent term is the primary driver; for certain categories, regulatory exclusivity adds a buffer.

What drives exclusivity timing?

• Patent filing date and patent term adjustment (PTA) or terminal disclaimers
• US market exclusivity (NCE, orphan, pediatric) where applicable
• Data exclusivity where there is new chemical entity status
• Orange Book continuity for NDA(s) and supplements

When does a membrane transport modulator lose exclusivity?

Most products in this class lose exclusivity on:

• The expiration of the latest, still-effective US composition-of-matter or formulation patent, not the earliest MoA patent.
• Loss of pediatric exclusivity or end of any orphan-related add-ons when relevant.
• For combination products, the last expiring component that anchors the claim set often determines the exit date.

What is the Orange Book status of membrane transport modulators?

Orange Book coverage is central because Paragraph IV challenges target listed patents. In practice:

• Commercially protected products maintain multiple Orange Book-listed patents tied to different aspects of the drug.
• The “Orange Book strategy” is used to align litigation risk with the sponsor’s strongest, most enforceable claims.

How do Orange Book listing strategies shape generic entry?

Sponsors typically list:

• Composition-of-matter patents with the broadest coverage first
• Formulation/salt/polymorph patents that are harder to design around
• Method-of-use patents that match label and dosing mechanics

Generics typically attempt to:

• Launch at-risk via Paragraph IV if they can find a non-infringing design-around
• Seek carve-outs or narrow generic labels that avoid method-of-use infringement

Which companies are challenging transporter-modulator patents via Paragraph IV?

Paragraph IV dynamics in this class follow the general pattern in complex transporter biology:

• Challengers are more likely where the sponsor’s estate includes multiple formulation and solid-state patents that are vulnerable to design-around.
• Challenges are less likely where the estate anchors on composition claims that remain broad and enforceable.

What generic entry risks are most common?

• Early product development that assumes design-around succeeds when courts hold formulation or solid-state claims valid and infringed
• Reliance on label carve-outs that fail because method-of-use claims track dosing regimens actually used
• Manufacturing process differences that do not avoid infringement where claims are product-defined rather than process-defined

What patent litigation affects membrane transport modulators most?

Litigation in transporter-modulator space is usually concentrated around:

• Solid-state and polymorph infringement (product-by-process disputes)
• Method-of-use where the generic label is narrow but overlaps physician practice
• Combination regimens where the generic’s proposed co-administration overlaps sponsor’s patent claims

What matters for outcomes?

• Claim construction around “modulates,” “inhibits,” “binds,” and functional equivalence
• Evidence of transporter-specific effects at clinically relevant concentrations
• Comparative dissolution, stability, or crystallinity profiles for formulation disputes
• Proving or refuting infringement in the presence of multiple possible polymorphs during manufacture

How do formulation patents shape biosimilar and generic risk?

Membrane transport modulators often require careful control of exposure, which increases the importance of formulation IP.

What formulation concepts drive enforceable patent claims?

• Solubility and permeability modifiers that change effective absorption
• Release kinetics affecting peak-to-trough exposure
• Particle size and morphology affecting efflux susceptibility
• Solid-state forms that alter dissolution rate and stability

How does this change generic strategy?

Generic sponsors may:

• Substitute a different salt or solid form
• Change excipient system
• Alter release profile Each change can trigger a new infringement inquiry if the sponsor’s claims cover equivalents or if the alternative still falls within claim boundaries.

What is the competitive landscape for major transporter-modulating drugs?

The competitive landscape depends on which transporter family anchors the leading therapies. The class typically clusters competitors by:

• Target transporter family (efflux vs uptake vs ion transport)
• Route of administration (oral, inhaled, topical, injectable)
• Indication concentration (oncology, renal/hepatic disease, GI, CNS/psychiatry, metabolic)

How does mechanism translate into competitor count?

Transporter-selective MoA and biomarker-defined populations reduce direct competition but increase pricing resilience. Transporter broadening and off-target profiles tend to invite more competitors and faster label expansion.

How does market demand interact with patent expiration and launch timing?

Transporter modulators are not purely “single endpoint” assets; many have exposure-managed regimens. Launch planning therefore tracks:

• When the last Orange Book-listed patent expires
• When patent litigation ends (stay lifting, consent judgments, or final judgments)
• When any exclusivity add-ons end

What are common launch scenarios?

1. Full at-launch entry after all relevant patents expire
2. Launch under an agreement (authorized generic or licensing)
3. Delayed entry due to unresolved appeals or settlement terms
4. Design-around entry with a narrower label and risk allocation

Key takeaways

• Membrane transport modulators typically have layered IP: core composition plus formulation/solid-state and method-of-use or regimen claims tied to exposure management and transporter biology.
• Competitive risk concentrates around Orange Book-listed patents that cover polymorph/salt/formulation and method-of-use aligned to label dosing.
• Exclusivity timing is usually governed by the last enforceable US composition or formulation patent, with regulatory exclusivities adding a short buffer where applicable.
• Litigation is most common where courts must resolve functional claim language (“modulates/inhibits”) and product infringement questions (solid form, dissolution, and manufacturing equivalence).
• Generic and biosimilar competitors face the highest risk when sponsor estates cover not just the API but also delivery and the clinically used dosing regimens that reflect transporter effects.

FAQs

1) What patent families are most likely to block a generic launch of a membrane transporter modulator?

Composition-of-matter plus solid-state (polymorph/salt/co-crystal) and label-aligned method-of-use patents are usually the most launch-blocking categories because they are harder to design around without risking clinical or exposure differences.

2) Do formulation patents matter more than MoA patents for transporter modulators?

Often yes. In transporter-driven exposure settings, formulation determines bioavailability and efflux susceptibility, which can make formulation claims more infringable and less easily avoided than broad MoA concepts.

3) How do Paragraph IV challenges typically attempt to carve around transporter modulator claims?

Challengers typically target non-infringement via alternative solid forms or formulations, or via label/dosing changes intended to avoid method-of-use overlap.

4) When do settlement agreements usually accelerate entry for transporter modulators?

Settlements tend to accelerate entry when they resolve stays and define non-infringement positions around specific patents, often coupling earlier commercial launch with royalty or authorized-generic terms.

5) What regulatory pathway details most affect patent strategy for transporter modulators?

The sponsor’s label scope and dosing regimen alignment with transporter-driven effects are central because method-of-use and formulation patents often track those label mechanics during enforcement and generic carve-out negotiations.

---

References

1. National Library of Medicine (NLM). MeSH Browser: “Membrane Transport Modulators.”
2. U.S. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”).
3. U.S. FDA. 21 U.S.C. § 355(c)(3) and related exclusivity frameworks (as implemented in FDA guidance and Orange Book listing practices).